- Home
- MAIA vs ALVR Comparison
MAIA vs ALVR Comparison
Compare MAIA & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ALVR
- Stock Information
- Founded
- MAIA 2018
- ALVR 2013
- Country
- MAIA United States
- ALVR United States
- Employees
- MAIA N/A
- ALVR N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAIA Health Care
- ALVR Health Care
- Exchange
- MAIA Nasdaq
- ALVR Nasdaq
- Market Cap
- MAIA 62.4M
- ALVR 87.7M
- IPO Year
- MAIA 2022
- ALVR 2020
- Fundamental
- Price
- MAIA $2.82
- ALVR $0.90
- Analyst Decision
- MAIA
- ALVR Sell
- Analyst Count
- MAIA 0
- ALVR 5
- Target Price
- MAIA N/A
- ALVR $1.00
- AVG Volume (30 Days)
- MAIA 60.0K
- ALVR 155.6K
- Earning Date
- MAIA 11-05-2024
- ALVR 11-04-2024
- Dividend Yield
- MAIA N/A
- ALVR N/A
- EPS Growth
- MAIA N/A
- ALVR N/A
- EPS
- MAIA N/A
- ALVR N/A
- Revenue
- MAIA N/A
- ALVR N/A
- Revenue This Year
- MAIA N/A
- ALVR N/A
- Revenue Next Year
- MAIA N/A
- ALVR N/A
- P/E Ratio
- MAIA N/A
- ALVR N/A
- Revenue Growth
- MAIA N/A
- ALVR N/A
- 52 Week Low
- MAIA $0.82
- ALVR $0.58
- 52 Week High
- MAIA $5.99
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- ALVR 69.10
- Support Level
- MAIA $2.36
- ALVR $0.74
- Resistance Level
- MAIA $2.72
- ALVR $0.91
- Average True Range (ATR)
- MAIA 0.22
- ALVR 0.06
- MACD
- MAIA 0.02
- ALVR 0.01
- Stochastic Oscillator
- MAIA 72.28
- ALVR 94.50
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.